Asimov licensed its LV Edge Packaging lentiviral production cell line to CDMO AGC Biologics, enabling single‑plasmid transfection workflows and reducing GMP plasmid costs, supply‑chain risk and process complexity. AGC said it will offer the system from its Milan Cell and Gene Center of Excellence for customers globally. Trenchant BioSystems released internal and external validation data for its AutoCell automated CGT manufacturing platform, claiming up to a 7‑fold increase in gene‑modified cell yield and an 80% reduction in cost versus existing methods, with potential vein‑to‑vein timelines shortened from ~6 weeks to 2.5 days in prototype runs. External validation by Invetech confirmed key unit‑operation performance. Taken together, the deals and prototype data reflect a drive to de‑risk and scale CGT manufacturing through cell‑line engineering and automation, addressing throughput, cost and quality hurdles that limit broader patient access to these therapies.